Login / Signup

Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.

Andrea MarcellusiChiara BiniMassimo AndreoniLoredana SarmatiJaime EspinJuan P HorcajadaThomas CzypionkaDavide AndrettaPaolo SciattellaGiampiero FavatoFrancesco S Mennini
Published in: Clinical drug investigation (2020)
The introduction of dalbavancin in a new patient pathway to treat non-severe ABSSSI could generate a significant reduction in hospitalized patients and the overall patient length of stay in hospital.
Keyphrases
  • case report
  • soft tissue
  • liver failure
  • wound healing
  • healthcare
  • drug induced
  • early onset
  • respiratory failure
  • intensive care unit
  • emergency department
  • hepatitis b virus
  • adverse drug
  • acute care